BioCentury
ARTICLE | Clinical News

Alkermes submits NDA to FDA for Biogen-partnered MS candidate

January 4, 2019 1:19 AM UTC

Alkermes plc (NASDAQ:ALKS) submitted an NDA to FDA under under section 505(b)(2) of the Food, Drug and Cosmetic Act seeking approval of diroximel fumarate (BIIB098) to treat relapsing forms of multiple sclerosis. Alkermes' partner Biogen Inc. (NASDAQ:BIIB) intends to market the product under the brand name Vumerity...

BCIQ Company Profiles

Alkermes plc

Biogen Inc.